TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03262818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound
Description: -Will be performed by US technologists at Washington University School of Medicine and read by Dr. Cary Siegel or Dr. Kathryn Robinson

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound/Photoacoustic imaging
Description: -The light illumination for the photoacoustic imaging system is provided by a wavelength-tunable Ti:Sapphire laser (LOTIS TII), optically pumped by an Nd:YAG laser (LOTIS TII) at 532 nm wavelength.
Study: NCT03030508

Intervention type: OTHER
Intervention: No intervention
Study: NCT01818908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-EPOCH
Description: DA-EPOCH regimen
Study: NCT02375568

Intervention type: OTHER
Intervention: 103024-F
Description: mesenchymal stem cell isolation
Study: NCT03941457

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BiCAR-NK cells (ROBO1 CAR-NK cells)
Description: The subject will be observed for any side effects during this time and all the adverse events will be recorded.
Study: NCT05215860

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco and areca nut cessation counselling with standard management for Oral Potentially Malignant Disorders
Description: WHO toolkit for Tobacco cessation (5A's and 5R's model)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco and areca nut cessation counselling with standard management for Oral Potentially Malignant Disorders
Description: WHO toolkit for Tobacco cessation (5A's and 5R's model)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visual exposure to personal intraoral photographs of oral lesions at baseline and review
Description: Chairside digital intraoral photographs of oral potentially malignant disorder with smart phone and showing the photograph to the participant explaining the abnormal areas of concern
Study: NCT00211835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Individual psychotherapy focused on identifying and correcting maladaptive cognitions and behaviors with the goal of improving mood. The intervention has adapted CBT specifically to address cognitive deficits associated with TBI, which compound the cognitive distortions typical of depression. CBT therapists embed compensatory strategies within treatment sessions to address cognitive limitations of each participant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy
Description: A client-centered individual psychotherapy treatment approach designed to address depressive disorders commonly experienced by individuals following a TBI. In line with traditional supportive psychotherapy approaches, the objective of SPT is to improve the individual's ability to deal with problems of daily living more effectively through problem identification, praise, reassurance, encouragement, psychoeducation, advice, anticipatory guidance, and expanding awareness.
Study: NCT01727115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Formula Feeding
Description: Assigned formula (Althera® or Nutramigen®) for a 4 weeks period.~* If the challenge is positive: The children continue the assigned formula~* If the challenge is negative: A Follow up formula is given~  * (Nan pro2) if child \> 6 months~ * (Nan pro1) if child \< 6 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant Formula Feeding
Description: Assigned formula (Althera® or Nutramigen®) for a 4 weeks period.~* If the challenge is positive: The children continue the assigned formula~* If the challenge is negative: A Follow up formula is given~  * (Nan pro2) if child \> 6 months~ * (Nan pro1) if child \< 6 months
Study: NCT02114125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: group-based physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: group-based physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: group-based physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: individual-based, multi-domains cognitive training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: individual-based, multi-domains cognitive training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: individual-based, multi-domains cognitive training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: individual-based, multi-domains cognitive training
Study: NCT04401618

Intervention type: OTHER
Intervention: Retrospective evaluation of RMGI and GIC Class V Restorations
Description: Retrospective evaluation of RMGI and GIC Class V Restorations that were placed by dental students over the last three years were evaluated using the modified USPHS criteria using mirrors and probes.

Intervention type: OTHER
Intervention: Retrospective evaluation of RMGI and GIC Class V Restorations
Description: Retrospective evaluation of RMGI and GIC Class V Restorations that were placed by dental students over the last three years were evaluated using the modified USPHS criteria using mirrors and probes.
Study: NCT01083394

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTA
Description: PTA using a conventional balloon

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTA with PEB
Description: PTA using a paclitaxel eluting balloon

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Transluminal Angioplasty (PTA)
Description: Percutaneous transluminal angioplasty with conventional balloon or paclitaxel-eluting balloon

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty (PTA)
Description: Percutaneous transluminal angioplasty with conventional balloon or paclitaxel-eluting balloon
Study: NCT04158440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab
Description: Biological: Toripalimab 240 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )
Description: Biological: Placebo by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W
Study: NCT01883843

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham tDCS + TOCT
Description: Every day will be given a continuous low-intensity stimulation of 0.5mA (for a current density of 60μA/cm2) only for 10 seconds at the beginning and at the end of the stimulation for 10 consecutive days after any rehabilitative treatment. The mounting of electrodes for sham stimulation is the same used for the experimental group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real tDCS + TOCT
Description: Every day will be given continuous stimulation duration of 15 minutes with intensity of 0.5 mA (for a current density of 60μA/cm2), generated by a constant current stimulator rechargeable batteries for 10 consecutive days after any rehabilitation treatment in the gym. Two sponge electrodes are placed, soaked in saline solution, fixed by an elastic band, the anode consists of an electrode oblong 8cm2 positioned at M1 area on the lower limb affection (following the medial sagittal axis, with the center of the electrode positioned at one centimeter laterally to the vertex) while the cathode (48cm2) is placed in the contralateral supraorbitale area as reference electrode. The current reaches 0.5mA and decreases with a ramp of 10 seconds.
Study: NCT03441776

Intervention type: OTHER
Group type: OTHER
Intervention: Generalized Vestibular Rehabilitation Treatment
Description: These treatment visits are available twice a week and each visit lasts 45 minutes. Individuals receiving GVRT are allowed to choose the frequency at which they want to attend and the program is designed for each subject to complete 8 visits within a period between 4 and 8 weeks. The ideal number of patients receiving treatment at each class is from 3 to 6 but the system has capacity for a maximum of 8. GVRT is a standard of care treatment option and is not considered research.

Intervention type: OTHER
Group type: OTHER
Intervention: Individualized Vestibular Rehabilitation Treatment
Description: Individuals receiving IVRT are scheduled depending on their individual needs and PT availability. These visits require one-on-one time with a PT. Individuals are commonly seen by the PT 3 times at two week intervals. These visits last 30 minutes and include PT evaluation designed to instruct patients on exercises for them to perform on their own. IVRT is a standard of care treatment option and is not considered research.
Study: NCT04492839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intestinal adsorbent
Description: Participants will consume the 15ml of the intestinal adsorbent (3.5 g Silicon dioxide in 100 ml Silicic acid gel, Preservatives: Sorbic acid (E 200), Sodium benzoate (E 211). ) three times daily for 10 days. There are no known side effects of the medical device. The product is a class IIa medical device under the European council directive and the product will be used within it's current indications.
Study: NCT01074450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole Dihydrochloride
Description: 0.25 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramipexole Dihydrochloride
Description: 0.25 mg Tablet
Study: NCT03879122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab 5 MG/ML
Description: Ipilimumab will be administered on day 1 of each cycle every 3 weeks. In arm 3, ipilimumab should be started at least 2 weeks but no later than 120 days after surgical castration or the first dose of LHRH analogue. Patients should receive 2 doses of ipilimumab (6 weeks). It will be followed, 3 weeks later, by 3 cycles of docetaxel and by 2 additional doses of ipilimumab and 3 more cycles of docetaxel. Four weeks later, Nivolumab will be administered on day 1 every 2 weeks until a maximum of 24 doses (48 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 MG/ML
Description: Nivolumab will be administered every 2 weeks, until clinical progression or a maximum of 24 doses. Nivolumab should be started 4 weeks after the last dose of docetaxel, providing all the adverse effects have recovered, as if a new cycle of docetaxel were to be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 MG/ML
Description: Nivolumab will be administered every 2 weeks, until clinical progression or a maximum of 24 doses. Nivolumab should be started 4 weeks after the last dose of docetaxel, providing all the adverse effects have recovered, as if a new cycle of docetaxel were to be administered
Study: NCT01923363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin/Tazobactam Standard Dose to High Dose
Description: Patients will receive a standard dose of piperacillin/tazobactam, then will have subsequent pharmacokinetic analyses on the blood concentrations drawn while on standard dose. Patients will be switched to higher dose after receiving the standard dose, with subsequent pharmacokinetic analyses performed on those blood concentrations while on higher dose. These pharmacokinetics of each dosing regimen will be compared.
Study: NCT03879122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel should be given on day 1 every 21 days, for up to 6 cycles (1 cycle = 21 days). Docetaxel should be started within 7 working days from the date of randomization in the arm 1 and 2.~In arm 3, docetaxel will be given 3 weeks after the last dose of the previous treatment, providing all the side effects are grade ≤1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel should be given on day 1 every 21 days, for up to 6 cycles (1 cycle = 21 days). Docetaxel should be started within 7 working days from the date of randomization in the arm 1 and 2.~In arm 3, docetaxel will be given 3 weeks after the last dose of the previous treatment, providing all the side effects are grade ≤1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel should be given on day 1 every 21 days, for up to 6 cycles (1 cycle = 21 days). Docetaxel should be started within 7 working days from the date of randomization in the arm 1 and 2.~In arm 3, docetaxel will be given 3 weeks after the last dose of the previous treatment, providing all the side effects are grade ≤1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADT (androgen deprivation therapy)
Description: Androgen deprivation therapy per the standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT (androgen deprivation therapy)
Description: Androgen deprivation therapy per the standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT (androgen deprivation therapy)
Description: Androgen deprivation therapy per the standard of care
Study: NCT02779088

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise and nutrition
Description: Exercise:muscle strengthening exercise Nutrition: 7.2 g branched chain amino acid every day and 1200 mg Ca+800 IU Vitamin D3
Study: NCT01923220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HO/02/02 20µg
Description: Interventions involving HO/02/02 20µg VS. Aloe Vera Jel (SOC). Treatment will be applied topically once daily

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Aloe Vera Jel
Description: To be applied topically once daily
Study: NCT01936688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3222 200 mg
Description: MK-3222 200 mg administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3222 100 mg
Description: MK-3222 100 mg administered SC.
Study: NCT02779088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and nutrition
Description: Exercise:muscle strengthening exercise Nutrition: 7.2 g branched chain amino acid every day and 1200 mg Ca+800 IU Vitamin D3
Study: NCT00759265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance training
Description: During 24 weeks, the patients of the intervention group will participate in a resistance training program. Two subsequent intervention programmes will be offered. Initially the first 12 week resistance trainings stage will aimed at improving function of lower leg muscles; subsequently a more extended programme affecting total limb musculature (lower- and upper leg) will be provided (also 12 weeks).~During these trainings period, patients will train 3 times a week; once a plenary training session of 1,5 hour provided by a physical therapist. And 2 trainings sessions of half an hour each, by them selves at home.
Study: NCT01936688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to MK-3222
Description: Matching placebo to MK-3222 administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to MK-3222
Description: Matching placebo to MK-3222 administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Etanercept
Description: Matching placebo to etanercept for subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Etanercept
Description: Matching placebo to etanercept for subcutaneous injection.
Study: NCT02624063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir + Sofosbuvir
Description: Sofosbuvir 400 mg tablet + Daclatasvir 60 mg tablet oral dosing once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir + Sofosbuvir
Description: Sofosbuvir 400 mg tablet + Simeprevir 150 mg tablet oral dosing once daily for 12 weeks
Study: NCT01936688

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Etanercept
Description: Matching placebo to etanercept for subcutaneous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept 50 mg
Description: Etanercept 50 mg for subcutaneous injection.
Study: NCT02005445

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Continuous positive airway pressure

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: HLSE
Description: Healthy living and sleep education
Study: NCT01443754

Intervention type: PROCEDURE
Intervention: LIMA-LAD surgical revascularization
Description: Off-pump coronary artery bypass (OPCAB) in which coronary revascularization is performed on the beating heart will be followed, the choice of the technical solutions being left at the discretion of the cardiac surgeon:~* use of a left anterior small thoracotomy (LAST), LIMA harvesting using thoracoscopic methods and manual anastomosis of the LIMA-LAD using a stabilization device;~* minimally invasive direct coronary bypass surgery (MIDCAB). The procedures can be performed alone or in combination with one another.
Study: NCT03587025

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: Amitriptyline compared with placebo for preemptive analgesia in women after abdominal hysterectomy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03179111

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum Pressure
Description: There will be two arms in this study. The participants recruited for this study are those who have been screened and planned for elective bariatric surgery.The pneumoperitoneum pressure will be adjusted to either 8-10mmHg or 12-15mmHg until a clear operating field is obtained by the surgeon. Low pneumoperitoneum pressure has been expected to give a clearer and better surgical view than standard pneumoperitoneum pressure. Participants under the low pressure group are expected to have lesser pain score on abdominal pain and shoulder tip pain as compared to participants in the standard pressure group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum Pressure
Description: There will be two arms in this study. The participants recruited for this study are those who have been screened and planned for elective bariatric surgery.The pneumoperitoneum pressure will be adjusted to either 8-10mmHg or 12-15mmHg until a clear operating field is obtained by the surgeon. Low pneumoperitoneum pressure has been expected to give a clearer and better surgical view than standard pneumoperitoneum pressure. Participants under the low pressure group are expected to have lesser pain score on abdominal pain and shoulder tip pain as compared to participants in the standard pressure group.
Study: NCT01610713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW-1000-02
Description: Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
Study: NCT03916185

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV ΔNS2/Δ1313/I1314L Vaccine
Description: 10\^6 plaque-forming units (PFU); administered as nose drops

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV 6120/ΔNS2/1030s Vaccine
Description: 10\^5 plaque-forming units (PFU); administered as nose drops

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV 276 Vaccine
Description: 10\^5 plaque-forming units (PFU); administered as nose drops

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as nose drops
Study: NCT00503776

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise intervention
Description: Patients undergo low weight resistance training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Patients undergo low weight resistance training.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate
Description: Given subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate
Description: Given subcutaneously

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic dietary intervention
Description: Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic dietary intervention
Description: Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic dietary intervention
Description: Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic dietary intervention
Description: Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.